In terms of weight loss outcomes, the TRIUMPH-1 trial suggests that Retatrutide may provide superior results, with up to a 28.3% weight loss over 80 weeks compared to tirzepatide's 20.9% achieved in other studies
It also reduces the risk of cardiovascular death, heart attack and stroke in patients who have overweight or obesity
In the same meta-analysis SGLT-2 were superior to GLP-1 receptor agonists in terms of reducing hospitalization for HF and the composite renal outcome, while GLP-1 receptor agonists were the only drug that reduced non-fatal stroke (69)
Ypsomed responds to the challenge of adherence and therapy management by providing the SmartPilot TM for YpsoMate, a reusable add-on that transforms YpsoMate into a fully connected smart product system
[DOI] [PubMed] [Google Scholar] 9.Chiasson J.L., Josse R.G., Gomis R., Hanefeld M., Karasik A., Laakso M., STOP-NIDDM Trail Research Group Acarbose for prevention of type 2 diabetes mellitus: The STOP-NIDDM randomised trial
Your provider should review your medications, blood pressure history, cardiovascular risk, and overall health